Cargando…

Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone

Detalles Bibliográficos
Autores principales:	Alter, Markus, Ott, Ina, von Websky, Karoline, Tsuprykov, Oleg, Sharkovska, Yuliya, Krause-Relle, Katharina, Raila, Jens, Henze, Andrea, Kretschmer, Axel, Stasch, Johannes-Peter, Hocher, Berthold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363201/ http://dx.doi.org/10.1186/1471-2210-11-S1-P1

Ejemplares similares

Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade
por: Ott, Ina M., et al.
Publicado: (2012)

Repurposing ARBs as treatments for breast cancer
por: George, Amee J., et al.
Publicado: (2017)

In silico prediction of ARB resistance: A first step in creating personalized ARB therapy
por: Anderson, Shane D., et al.
Publicado: (2020)

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020)

ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

The histological spectrum of ARB‐induced gastritis
por: Storozuk, Tanner, et al.
Publicado: (2022)

Need to Revisit Step Therapy for ARBs
por: Ram, C. Venkata, et al.
Publicado: (2007)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis
por: Ma, Linlin, et al.
Publicado: (2021)

Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats
por: Geschka, Sandra, et al.
Publicado: (2011)

Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats
por: Geschka, Sandra, et al.
Publicado: (2011)

Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension
por: Kalk, Philipp, et al.
Publicado: (2009)

The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy
por: Sun, Liping, et al.
Publicado: (2023)

A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization – results from IQVIA™ Disease Analyzer Germany
por: Hedenmalm, Karin, et al.
Publicado: (2023)

ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020)

The role of ACEIs/ARBs in COVID-19: Friend or foe?
por: Zhou, Zhe, et al.
Publicado: (2020)

Clinical and Genetic Findings of Autosomal Recessive Bestrophinopathy (ARB)
por: Habibi, Imen, et al.
Publicado: (2019)

Controversy regarding ACE inhibitors / ARBs in COVID-19
por: Soria Arcos, Federico, et al.
Publicado: (2020)

Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
por: Flacco, Maria Elena, et al.
Publicado: (2020)

sGC redox regulation and asthma
por: Stuehr, Dennis J, et al.
Publicado: (2015)

ARBs and risk of cancer: international and South African expert comment
Publicado: (2010)

The place of ARBs in heart failure therapy: is aldosterone suppression the key?
por: Markan, Uma, et al.
Publicado: (2019)

ACEI inhibitors and ARBs do not increase severity of COVID-19
Publicado: (2020)

Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
por: Rico-Mesa, Juan Simon, et al.
Publicado: (2020)

Is there a difference in the effect between the ACEI and ARB on COVID‐19?
por: Chen, Jie, et al.
Publicado: (2020)

ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No?
por: Gong, Jin, et al.
Publicado: (2021)

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

ASSOCIATION BETWEEN IN-HOSPITAL MORTALITY AND ACE/ARB INHIBITOR USAGE
por: Ruge, Max, et al.
Publicado: (2022)

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
por: Duprez, Daniel, et al.
Publicado: (2011)

Structural insights into sGC activation by different activators
por: van den Akker, Focco, et al.
Publicado: (2011)

The sGC stimulator BAY 41-8543 in a rat model of hypertension-induced heart failure
por: Haase, N, et al.
Publicado: (2015)

MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB
por: Weber, Martina, et al.
Publicado: (2011)

A Toolkit for ARB to Integrate Custom Databases and Externally Built Phylogenies
por: Essinger, Steven D., et al.
Publicado: (2015)

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?
por: Dézsi, Csaba András
Publicado: (2016)

Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
por: Huang, Ying, et al.
Publicado: (2020)

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
por: Lee, Ivan T., et al.
Publicado: (2020)

Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
por: Khan, Sikandar Hayat, et al.
Publicado: (2020)

COVID-19-related deaths not increased with ACE inhibitor or ARB use
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7phn4o9vp1g100bo9pl99tiokd